Your browser doesn't support javascript.
loading
Hepatitis A vaccine immune response 22 years after vaccination.
Mosites, Emily; Gounder, Prabhu; Snowball, Mary; Morris, Julie; Spradling, Philip; Nelson, Noele; Bulkow, Lisa; Bruce, Michael; McMahon, Brian.
Afiliación
  • Mosites E; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska.
  • Gounder P; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska.
  • Snowball M; Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
  • Morris J; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska.
  • Spradling P; Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Nelson N; Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia.
  • Bulkow L; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska.
  • Bruce M; Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, Alaska.
  • McMahon B; Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska.
J Med Virol ; 90(8): 1418-1422, 2018 08.
Article en En | MEDLINE | ID: mdl-29663458
In the United States, the incidence of hepatitis A virus (HAV) infection has been reduced through universal childhood vaccination. However, the duration of immunogenicity for the hepatitis A vaccine is not known. We report on the 22 year follow-up time point of a cohort of Alaska children who were randomized to three different vaccine schedules: A) 0, 1, and 2 months; B) 0, 1, and 6 months; and C) 0, 1, and 12 months. Among 46 participant available for follow-up, 40 (87%) maintained protective levels of anti-hepatitis A antibody. These results indicate that a supplemental booster dose is not yet necessary at or before the 22-year time point.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Hepatitis A / Virus de la Hepatitis A / Anticuerpos de Hepatitis A Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Child / Child, preschool / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Med Virol Año: 2018 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Hepatitis A / Virus de la Hepatitis A / Anticuerpos de Hepatitis A Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Child / Child, preschool / Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Med Virol Año: 2018 Tipo del documento: Article